Selected research
Market Outlook & Growth Opportunities
Global Coagulation Factor XI Market Outlook and Growth Opportunities 2026
Market perspective
The global Coagulation Factor XI market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Coagulation Factor XI is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Coagulation Factor XI is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Coagulation Factor XI is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Coagulation Factor XI market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Coagulation Factor XI market include Bristol-Myers Squibb Company, Cambryn Biologics LLC, eXithera Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc., LegoChem Biosciences, Inc and Bayer AG, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Coagulation Factor XI market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Coagulation Factor XI and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Coagulation Factor XI revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Coagulation Factor XI market.
Coagulation Factor XI Segment by Company
Bristol-Myers Squibb Company
Cambryn Biologics LLC
eXithera Pharmaceuticals, Inc
Ionis Pharmaceuticals, Inc.
LegoChem Biosciences, Inc
Bayer AG
Coagulation Factor XI Segment by Type
MR-1007
IONIS-FXIRx
EP-7041
BMS-262084
AB-022
Others
Coagulation Factor XI Segment by Application
Thrombosis
Acute Ischemic Stroke
Bleeding and Clotting Disorders
Others
Coagulation Factor XI Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Coagulation Factor XI status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Coagulation Factor XI key companies, revenue, market share, and recent developments.
3. To split the Coagulation Factor XI breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Coagulation Factor XI market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Coagulation Factor XI significant trends, drivers, influence factors in global and regions.
6. To analyze Coagulation Factor XI competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Coagulation Factor XI market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Coagulation Factor XI and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Coagulation Factor XI.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Coagulation Factor XI industry.
Chapter 3: Detailed analysis of Coagulation Factor XI company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Coagulation Factor XI in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Coagulation Factor XI in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- MR-1007
- IONIS-FXIRx
- EP-7041
- BMS-262084
- AB-022
- Others
Applications
- Thrombosis
- Acute Ischemic Stroke
- Bleeding and Clotting Disorders
- Others
Companies covered
- Bristol-Myers Squibb Company
- Cambryn Biologics LLC
- eXithera Pharmaceuticals, Inc
- Ionis Pharmaceuticals, Inc.
- LegoChem Biosciences, Inc
- Bayer AG
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Coagulation Factor XI Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Coagulation Factor XI Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Coagulation Factor XI Market Dynamics
- 2.1 Coagulation Factor XI Industry Trends
- 2.2 Coagulation Factor XI Industry Drivers
- 2.3 Coagulation Factor XI Industry Opportunities and Challenges
- 2.4 Coagulation Factor XI Industry Restraints
3 Coagulation Factor XI Market by Company
- 3.1 Global Coagulation Factor XI Company Revenue Ranking in 2025
- 3.2 Global Coagulation Factor XI Revenue by Company (2021-2026)
- 3.3 Global Coagulation Factor XI Company Ranking (2024-2026)
- 3.4 Global Coagulation Factor XI Company Manufacturing Base and Headquarters
- 3.5 Global Coagulation Factor XI Company Product Type and Application
- 3.6 Global Coagulation Factor XI Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Coagulation Factor XI Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Coagulation Factor XI Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Coagulation Factor XI Market by Type
- 4.1 Coagulation Factor XI Type Introduction
- 4.1.1 MR-1007
- 4.1.2 IONIS-FXIRx
- 4.1.3 EP-7041
- 4.1.4 BMS-262084
- 4.1.5 AB-022
- 4.1.6 Others
- 4.2 Global Coagulation Factor XI Sales Value by Type
- 4.2.1 Global Coagulation Factor XI Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Coagulation Factor XI Sales Value by Type (2021-2032)
- 4.2.3 Global Coagulation Factor XI Sales Value Share by Type (2021-2032)
5 Coagulation Factor XI Market by Application
- 5.1 Coagulation Factor XI Application Introduction
- 5.1.1 Thrombosis
- 5.1.2 Acute Ischemic Stroke
- 5.1.3 Bleeding and Clotting Disorders
- 5.1.4 Others
- 5.2 Global Coagulation Factor XI Sales Value by Application
- 5.2.1 Global Coagulation Factor XI Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Coagulation Factor XI Sales Value by Application (2021-2032)
- 5.2.3 Global Coagulation Factor XI Sales Value Share by Application (2021-2032)
6 Coagulation Factor XI Regional Value Analysis
- 6.1 Global Coagulation Factor XI Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Coagulation Factor XI Sales Value by Region (2021-2032)
- 6.2.1 Global Coagulation Factor XI Sales Value by Region: 2021-2026
- 6.2.2 Global Coagulation Factor XI Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Coagulation Factor XI Sales Value (2021-2032)
- 6.3.2 North America Coagulation Factor XI Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Coagulation Factor XI Sales Value (2021-2032)
- 6.4.2 Europe Coagulation Factor XI Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Coagulation Factor XI Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Coagulation Factor XI Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Coagulation Factor XI Sales Value (2021-2032)
- 6.6.2 South America Coagulation Factor XI Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Coagulation Factor XI Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Coagulation Factor XI Sales Value Share by Country, 2025 VS 2032
7 Coagulation Factor XI Country-level Value Analysis
- 7.1 Global Coagulation Factor XI Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Coagulation Factor XI Sales Value by Country (2021-2032)
- 7.2.1 Global Coagulation Factor XI Sales Value by Country (2021-2026)
- 7.2.2 Global Coagulation Factor XI Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.7.2 France Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.14.2 China Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.17.2 India Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Coagulation Factor XI Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Coagulation Factor XI Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Coagulation Factor XI Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Bristol-Myers Squibb Company
- 8.1.1 Bristol-Myers Squibb Company Company Information
- 8.1.2 Bristol-Myers Squibb Company Business Overview
- 8.1.3 Bristol-Myers Squibb Company Coagulation Factor XI Revenue and Gross Margin (2021-2026)
- 8.1.4 Bristol-Myers Squibb Company Coagulation Factor XI Product Portfolio
- 8.1.5 Bristol-Myers Squibb Company Recent Developments
- 8.2 Cambryn Biologics LLC
- 8.2.1 Cambryn Biologics LLC Company Information
- 8.2.2 Cambryn Biologics LLC Business Overview
- 8.2.3 Cambryn Biologics LLC Coagulation Factor XI Revenue and Gross Margin (2021-2026)
- 8.2.4 Cambryn Biologics LLC Coagulation Factor XI Product Portfolio
- 8.2.5 Cambryn Biologics LLC Recent Developments
- 8.3 eXithera Pharmaceuticals, Inc
- 8.3.1 eXithera Pharmaceuticals, Inc Company Information
- 8.3.2 eXithera Pharmaceuticals, Inc Business Overview
- 8.3.3 eXithera Pharmaceuticals, Inc Coagulation Factor XI Revenue and Gross Margin (2021-2026)
- 8.3.4 eXithera Pharmaceuticals, Inc Coagulation Factor XI Product Portfolio
- 8.3.5 eXithera Pharmaceuticals, Inc Recent Developments
- 8.4 Ionis Pharmaceuticals, Inc.
- 8.4.1 Ionis Pharmaceuticals, Inc. Company Information
- 8.4.2 Ionis Pharmaceuticals, Inc. Business Overview
- 8.4.3 Ionis Pharmaceuticals, Inc. Coagulation Factor XI Revenue and Gross Margin (2021-2026)
- 8.4.4 Ionis Pharmaceuticals, Inc. Coagulation Factor XI Product Portfolio
- 8.4.5 Ionis Pharmaceuticals, Inc. Recent Developments
- 8.5 LegoChem Biosciences, Inc
- 8.5.1 LegoChem Biosciences, Inc Company Information
- 8.5.2 LegoChem Biosciences, Inc Business Overview
- 8.5.3 LegoChem Biosciences, Inc Coagulation Factor XI Revenue and Gross Margin (2021-2026)
- 8.5.4 LegoChem Biosciences, Inc Coagulation Factor XI Product Portfolio
- 8.5.5 LegoChem Biosciences, Inc Recent Developments
- 8.6 Bayer AG
- 8.6.1 Bayer AG Company Information
- 8.6.2 Bayer AG Business Overview
- 8.6.3 Bayer AG Coagulation Factor XI Revenue and Gross Margin (2021-2026)
- 8.6.4 Bayer AG Coagulation Factor XI Product Portfolio
- 8.6.5 Bayer AG Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst